Free Trial
→ Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th... (From Banyan Hill Publishing) (Ad)tc pixel Free SQZ Stock Alerts

SQZ Biotechnologies (SQZ) Competitors

SQZ Biotechnologies logo
$0.02 0.00 (0.00%)
As of 05/22/2026
Compare

SQZ vs. SGLY, CISS, USDP, AIRTP, and RA

Should you buy SQZ Biotechnologies stock or one of its competitors? MarketBeat compares SQZ Biotechnologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SQZ Biotechnologies include Singularity Future Technology (SGLY), C3is (CISS), USD Partners (USDP), Air T (AIRTP), and Brookfield Real Assets Income Fund (RA). These companies are all part of the "transportation" industry.

How does SQZ Biotechnologies compare to Singularity Future Technology?

SQZ Biotechnologies (NYSE:SQZ) and Singularity Future Technology (NASDAQ:SGLY) are both small-cap transportation companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

Singularity Future Technology has lower revenue, but higher earnings than SQZ Biotechnologies. Singularity Future Technology is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61N/A
Singularity Future Technology$1.81M0.91-$3.91M-$1.77N/A

In the previous week, SQZ Biotechnologies' average media sentiment score of 0.00 equaled Singularity Future Technology'saverage media sentiment score.

Company Overall Sentiment
SQZ Biotechnologies Neutral
Singularity Future Technology Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SQZ Biotechnologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Singularity Future Technology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

SQZ Biotechnologies has a net margin of -369.96% compared to Singularity Future Technology's net margin of -493.25%. Singularity Future Technology's return on equity of -42.68% beat SQZ Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
SQZ Biotechnologies-369.96% -119.83% -59.90%
Singularity Future Technology -493.25%-42.68%-13.00%

SQZ Biotechnologies has a beta of 2.34, indicating that its share price is 134% more volatile than the broader market. Comparatively, Singularity Future Technology has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

38.5% of SQZ Biotechnologies shares are owned by institutional investors. Comparatively, 4.1% of Singularity Future Technology shares are owned by institutional investors. 16.0% of SQZ Biotechnologies shares are owned by insiders. Comparatively, 10.2% of Singularity Future Technology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

SQZ Biotechnologies and Singularity Future Technology tied by winning 6 of the 12 factors compared between the two stocks.

How does SQZ Biotechnologies compare to C3is?

SQZ Biotechnologies (NYSE:SQZ) and C3is (NASDAQ:CISS) are both small-cap transportation companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

C3is has higher revenue and earnings than SQZ Biotechnologies. SQZ Biotechnologies is trading at a lower price-to-earnings ratio than C3is, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61N/A
C3is$34.76M0.04$10.47M-$1.13 thousandN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SQZ Biotechnologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
C3is
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

38.5% of SQZ Biotechnologies shares are owned by institutional investors. Comparatively, 10.5% of C3is shares are owned by institutional investors. 16.0% of SQZ Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, C3is had 2 more articles in the media than SQZ Biotechnologies. MarketBeat recorded 2 mentions for C3is and 0 mentions for SQZ Biotechnologies. C3is' average media sentiment score of 0.10 beat SQZ Biotechnologies' score of 0.00 indicating that C3is is being referred to more favorably in the news media.

Company Overall Sentiment
SQZ Biotechnologies Neutral
C3is Neutral

SQZ Biotechnologies has a beta of 2.34, suggesting that its stock price is 134% more volatile than the broader market. Comparatively, C3is has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

C3is has a net margin of 15.28% compared to SQZ Biotechnologies' net margin of -369.96%. C3is' return on equity of 6.78% beat SQZ Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
SQZ Biotechnologies-369.96% -119.83% -59.90%
C3is 15.28%6.78%6.16%

Summary

C3is beats SQZ Biotechnologies on 9 of the 14 factors compared between the two stocks.

How does SQZ Biotechnologies compare to USD Partners?

SQZ Biotechnologies (NYSE:SQZ) and USD Partners (NYSE:USDP) are both small-cap transportation companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

In the previous week, SQZ Biotechnologies' average media sentiment score of 0.00 equaled USD Partners'average media sentiment score.

Company Overall Sentiment
SQZ Biotechnologies Neutral
USD Partners Neutral

38.5% of SQZ Biotechnologies shares are owned by institutional investors. Comparatively, 0.1% of USD Partners shares are owned by institutional investors. 16.0% of SQZ Biotechnologies shares are owned by insiders. Comparatively, 2.6% of USD Partners shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

SQZ Biotechnologies has a beta of 2.34, meaning that its share price is 134% more volatile than the broader market. Comparatively, USD Partners has a beta of -0.18, meaning that its share price is 118% less volatile than the broader market.

USD Partners has a net margin of -94.39% compared to SQZ Biotechnologies' net margin of -369.96%. USD Partners' return on equity of 0.00% beat SQZ Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
SQZ Biotechnologies-369.96% -119.83% -59.90%
USD Partners -94.39%N/A -28.33%

USD Partners has higher revenue and earnings than SQZ Biotechnologies. SQZ Biotechnologies is trading at a lower price-to-earnings ratio than USD Partners, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61N/A
USD Partners$72.32M0.00$17.77M-$1.06N/A

Summary

USD Partners beats SQZ Biotechnologies on 7 of the 11 factors compared between the two stocks.

How does SQZ Biotechnologies compare to Air T?

SQZ Biotechnologies (NYSE:SQZ) and Air T (NASDAQ:AIRTP) are both transportation companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

38.5% of SQZ Biotechnologies shares are owned by institutional investors. 16.0% of SQZ Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Air T has higher revenue and earnings than SQZ Biotechnologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61N/A
Air T$272.47MN/AN/AN/AN/A

In the previous week, SQZ Biotechnologies' average media sentiment score of 0.00 equaled Air T'saverage media sentiment score.

Company Overall Sentiment
SQZ Biotechnologies Neutral
Air T Neutral

Air T has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. Air T's return on equity of 0.00% beat SQZ Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
SQZ Biotechnologies-369.96% -119.83% -59.90%
Air T N/A N/A N/A

Summary

Air T beats SQZ Biotechnologies on 4 of the 6 factors compared between the two stocks.

How does SQZ Biotechnologies compare to Brookfield Real Assets Income Fund?

Brookfield Real Assets Income Fund (NYSE:RA) and SQZ Biotechnologies (NYSE:SQZ) are both transportation companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Brookfield Real Assets Income Fund has higher revenue and earnings than SQZ Biotechnologies. Brookfield Real Assets Income Fund is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Brookfield Real Assets Income Fund$64.90MN/AN/A-$0.11N/A
SQZ Biotechnologies$18.16M0.04-$79.46M-$2.61N/A

Brookfield Real Assets Income Fund has a net margin of 0.00% compared to SQZ Biotechnologies' net margin of -369.96%. Brookfield Real Assets Income Fund's return on equity of 0.00% beat SQZ Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Brookfield Real Assets Income FundN/A N/A N/A
SQZ Biotechnologies -369.96%-119.83%-59.90%

38.5% of SQZ Biotechnologies shares are held by institutional investors. 16.0% of SQZ Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Brookfield Real Assets Income Fund's average media sentiment score of 0.00 equaled SQZ Biotechnologies'average media sentiment score.

Company Overall Sentiment
Brookfield Real Assets Income Fund Neutral
SQZ Biotechnologies Neutral

Summary

Brookfield Real Assets Income Fund beats SQZ Biotechnologies on 5 of the 8 factors compared between the two stocks.

Get SQZ Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for SQZ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SQZ vs. The Competition

Export
MetricSQZ BiotechnologiesBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$708K$309.68M$6.38B$23.24B
Dividend YieldN/AN/A2.76%4.10%
P/E Ratio-0.01N/A20.9531.03
Price / Sales0.04185.14550.2524.91
Price / CashN/A22.4443.4925.10
Price / Book0.014.7810.324.78
Net Income-$79.46M-$132.96M$3.56B$1.07B
7 Day PerformanceN/A2.32%4.31%3.11%
1 Month PerformanceN/A30.63%1.73%2.28%
1 Year PerformanceN/A77.64%34.63%29.97%

SQZ Biotechnologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SQZ
SQZ Biotechnologies
N/A$0.02
flat		N/AN/A$708K$18.16MN/A1,620
SGLY
Singularity Future Technology
0.3918 of 5 stars		$0.42
-1.3%		N/A-57.1%$1.76M$1.81MN/A40
CISS
C3is
0.3713 of 5 stars		$2.63
+2.3%		N/A-99.5%$384K$34.76MN/AN/A
USDP
USD Partners
N/A$0.00
-96.7%		N/AN/A$3K$72.32MN/A90
AIRTP
Air T
N/A$18.98
-0.7%		N/A+12.1%$0.00$272.47MN/A500

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:SQZ) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
More than 60 million Americans can position themselves before the 107x gold repricing.
Tucked inside U.S. Code Title 31, Section 5117 is a provision allowing the Treasury to reprice America's gold ...
Americas Gold Company | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
You cannot escape this reality
The last time something like this happened was 1974 - a secret deal that quietly determined the financial fate...
Porter & Company | Sponsoredtc pixel
Your $29.97 book is free today
Bill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...
Profits Run | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Nearly Half of Americans Are Exposed
Dr. David Eifrig, former Goldman Sachs insider and CEO of one of the largest financial research firms in the w...
Stansberry Research | Sponsoredtc pixel